Johnson & Johnson Stock Santiago S.E.

Equities

JNJCL

US4781601046

Pharmaceuticals

End-of-day quote Santiago S.E. 06:00:00 2024-06-18 pm EDT 5-day change 1st Jan Change
155,930 CLP 0.00% Intraday chart for Johnson & Johnson 0.00% +14.33%
Sales 2024 * 88.79B 82,750B Sales 2025 * 92.1B 85,843B Capitalization 356B 331,481B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 4.01 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.86 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 131,900
Yield 2024 *
3.26%
Yield 2025 *
3.41%
Free-Float 77.08%
More Fundamentals * Assessed data
Dynamic Chart
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease CI
J&J: launches open, secure digital ecosystem CF
J&J: promising results in Crohn's disease CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints MT
Johnson & Johnson Sees Positive Trial Results for Tremfya DJ
Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease CI
J&J: FDA application in lung cancer CF
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer MT
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer CI
J&J: positive results in Sjögren's disease CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints MT
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study CI
EU regulator mandates label updates on CAR-T cancer therapies RE
J&J: encouraging trial in relapsing multiple myeloma CF
More news
6 months+14.33%
Current year+14.33%
More quotes
1 week
155 930.00
Extreme 155930
155 930.00
1 month
133 150.00
Extreme 133150
155 930.00
Current year
133 150.00
Extreme 133150
156 750.00
1 year
129 270.00
Extreme 129270
157 980.00
3 years
119 950.00
Extreme 119950
177 790.00
5 years
119 950.00
Extreme 119950
177 790.00
10 years
119 950.00
Extreme 119950
177 790.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change
24-06-19 155,930 0.00%
24-06-18 155,930 0.00%
24-06-17 155,930 0.00%
24-06-14 155,930 0.00%
24-06-13 155,930 0.00%

End-of-day quote Santiago S.E., June 18, 2024

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
147.8 USD
Average target price
171.7 USD
Spread / Average Target
+16.20%
Consensus